Antitumor activity of sorafenib in human cancer cell lines with acquired resistance to EGFR and VEGFR tyrosine kinase inhibitors

Treatment of non small cell lung cancer (NSCLC) and colorectal cancer (CRC) have substantially changed in the last years with the introduction of epidermal growth factor receptor (EGFR) inhibitors in the clinical practice. The understanding of mechanisms which regulate cells sensitivity to these dru...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	PloS one 2011-12, Vol.6 (12), p.e28841
Hauptverfasser:	Morgillo, Floriana, Martinelli, Erika, Troiani, Teresa, Orditura, Michele, De Vita, Ferdinando, Ciardiello, Fortunato
Format:	Artikel
Sprache:	eng
Schlagworte:	AKT protein Analysis Animals Anticancer properties Antineoplastic Agents - pharmacology Antitumor activity Benzenesulfonates - pharmacology Biology Biotechnology c-Kit protein Cancer Cancer therapies Cell Line, Tumor Cell Movement - drug effects Cell proliferation Cell Proliferation - drug effects Colorectal cancer Colorectal carcinoma Drug Resistance, Neoplasm - drug effects Drugs Epidermal growth factor Epidermal growth factor receptors ErbB Receptors - antagonists & inhibitors ErbB Receptors - metabolism Gefitinib Growth factors Humans Inhibitor drugs Inhibitors Inhibitory Concentration 50 Kinases Lung cancer Lung diseases MAP kinase Medicine Mice Mutation Neoplasm Invasiveness Niacinamide - analogs & derivatives Non-small cell lung carcinoma Phenols (Class of compounds) Phenylurea Compounds Protein Kinase Inhibitors - pharmacology Protein-tyrosine kinase Pyridines - pharmacology Raf protein Receptors, Vascular Endothelial Growth Factor - antagonists & inhibitors Receptors, Vascular Endothelial Growth Factor - metabolism Ret protein Signal Transduction - drug effects Sorafenib Survivin Targeted cancer therapy Tumor cell lines Tyrosine Tyrosine kinase inhibitors Vascular endothelial growth factor Vascular endothelial growth factor receptors Xenograft Model Antitumor Assays Xenografts
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!